Crohn’s disease : global R&D pipeline

(PhRMA 2016 Medicines in Development for Autoimmune Diseases)

products ( in phase III)

Please, select a region or a country :

Last EUROPE (28) new drug approval

flag

Last ISRAEL new drug approval

flag

Last NORWAY new drug approval

flag

Last SWITZERLAND new drug approval

flag

Please select a country on the map

indicator picto Estimated Incidence rate (per 100,000) : --

indicator picto Estimated number of new cases in 2017 (calculated) : --

Crohn’s disease : EPIDEMIOLOGICAL DATA COMPARISON

(compare data by selecting countries on the left map)

EPIDEMIOLOGICAL
INDICATOR
Europe
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Israel
Norway
Switzerland
Kuwait
Bahrain
Qatar
Arab Emirates
Oman
Saudi Arabia
Egypt
South Africa
Turkey
USA
Canada
Brazil
Argentina
Mexico
New Zealand
Australia
6.170.004.800.006.500.000.008.601.407.208.206.602.708.905.9012.700.000.000.001.306.200.663.000.506.700.007.308.307.305.006.001.600.450.000.000.000.000.940.001.792.207.1013.401.480.060.0016.5029.30
32 3760533027900483183915 2725 4603008862737 74600061 03925231810836503 4267944 60938730312916000028409561 67722 5174 7213 0232607376 818


Data reported in the “Europe” column of the table are the sum or
the average of all countries available in the DiseaseLens™

Disease highlights

Crohn’s Disease (CD) is a chronic and serious condition that causes painful inflammation of the gastrointestinal tract, usually affecting the small intestine or colon.

Up to one million people in Europe have CD and it affects men and women equally. It appears to run in families and occurs most often in people between the ages of 15 and 30, although it can occur at any age, including in children. People of Caucasian and Jewish origins have a higher risk of developing IBD compared with other racial and ethnic subgroups.

While the exact incidence of pediatric CD is unknown, it is estimated that 10% of new cases of CD occur in patients younger than 18 years of age or an estimated 140,000 children in Europe. Pediatric CD usually presents during the mid to late teens, but has also been detected in younger children.

Symptoms of CD can range from mild to severe. They tend to occur after meals, with pain usually centered at or below the naval, often in the lower right section of the abdomen. The most common symptoms of CD include abdominal pain, cramping, frequent diarrhea, fever, rectal bleeding (in adults), and weight loss (in children).

Source: http://worldibdday.org

Methodology

Precise incidence and prevalence of Crohn’s disease and ulcerative colitis have been limited by (1) a lack of gold standard criteria for diagnosis; (2) inconsistent case ascertainment; and (3) disease misclassification. The data that does exist suggests that the worldwide incidence rate of ulcerative colitis varies greatly between 0.5–24.5/100,000 persons, while that of Crohn’s disease varies between 0.1–16/100,000 persons worldwide, with the prevalence rate of IBD reaching up to 396/100,000 persons.(2) It is estimated that as many as 1.4 million people in the United States suffer from these diseases.

The main and most reliable publication comes from Molodecky. Whenever many figures are available, we take the most recent ones, as well as the highest figures, as it is a disease in constant progression.

From the CDC http://www.cdc.gov assessed September 2014

Breaking news

World IBD (Inflammatory Bowel Syndrome) Day is marked on 19 May each year. World IBD Day is led by patient organisation representing 35 countries on four continents from Argentina, Australia, Brazil, Canada, 27 European nations through the umbrella organisation EFCCA, Israel, Japan, New Zealand to the United States of America.

http://worldibdday.org

Sources : Molodecky et all, Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review, gastroenterology, 2012;142:46–54 Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013 May;7(4):322-37. |Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46-54. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013 May;7(4):322-37.